Related Experiment Video

Updated: May 4, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

8.9K

PI3-kinase inhibitors in chronic lymphocytic leukemia

Julie E Chang1, Brad S Kahl

  • 1University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave., 4007 Wisconsin Institute for Medical Research, Madison, WI, 53705, USA, jc2@medicine.wisc.edu.

Current Hematologic Malignancy Reports
|January 7, 2014
PubMed

Insights

Novel PI3K-delta inhibitors show promise for treating chronic lymphocytic leukemia (CLL), including high-risk cases. These targeted therapies offer good response rates and tolerability, with ongoing research into combination regimens.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • The phosphatidylinositol 3-kinase (PI3K) pathway is a key target for B-cell lymphoproliferative disorders.
  • PI3K-delta subunit inhibitors have demonstrated significant clinical activity in chronic lymphocytic leukemia (CLL).

Purpose of the Study:

  • To review the development and clinical activity of novel oral PI3K-delta inhibitors.
  • To discuss the efficacy of these agents in relapsed/refractory and high-risk CLL.
  • To examine combination therapy regimens and associated toxicities.

Main Methods:

  • Clinical trials evaluating idelalisib and IPI-145 in CLL patients.
  • Analysis of objective response rates, nodal responses, and tolerability.
  • Review of safety profiles, including common and noteworthy toxicities.

Main Results:

  • Objective response rates of 40-60% and nodal responses exceeding 70% in relapsed/refractory CLL.
  • High response rates observed in high-risk CLL with 17p and 11q deletions.
  • Favorable tolerability and activity demonstrated in combination chemotherapy regimens.

Conclusions:

  • PI3K-delta inhibitors represent a promising therapeutic strategy for CLL, particularly for chemotherapy-resistant disease.
  • Peripheral lymphocytosis is a common side effect due to altered lymphocyte trafficking.
  • Ongoing studies are exploring combination regimens to further enhance efficacy and manage toxicities.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
7.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K